Joel Hartman, MD
Allergy & Immunology · Winston Salem, NCNPI 1184606147
Payments from drug & device makers
Across 1,195 payments — averaging $626.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$597K
- Aimmune Therapeutics, Inc.$55K
- Genentech USA, Inc.$40K
- Amgen$21K
- Optinose US, Inc.$20K
- Novartis$5K
- plus $11K from 26 others
What the payments were for
- Consulting fees$58,4628%
- Speaking & faculty fees$616,35082%
- Travel & lodging$46,2236%
- Food & beverage$27,9424%
- Education$1530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 683 | $597,078 |
| Aimmune Therapeutics, Inc. | 32 | $54,877 |
| Genentech USA, Inc. | 61 | $39,840 |
| Amgen(2 entities) | 56 | $20,922 |
| Optinose US, Inc. | 69 | $20,317 |
| Novartis | 45 | $4,706 |
| AbbVie | 36 | $3,179 |
| Sanofi | 21 | $2,850 |
| Regeneron Healthcare Solutions, Inc. | 26 | $960 |
| Alk-abello, Inc | 4 | $957 |
| GSK | 44 | $804 |
| Pfizer | 33 | $572 |
| Blueprint Medicines Corporation | 5 | $320 |
| CSL Behring | 10 | $284 |
| Grifols USA, LLC | 6 | $198 |
| Biocryst US Sales Co., LLC | 7 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $182 |
| Galderma Laboratories, L.p. | 10 | $153 |
| Teva Pharmaceuticals USA, Inc. | 8 | $152 |
| Shire North American Group Inc | 7 | $121 |
| Hospira, Inc. | 7 | $104 |
| LEO Pharma Inc. | 4 | $85 |
| Covis Pharma GmbH | 5 | $75 |
| Incyte Corporation | 2 | $45 |
| Pharming Healthcare, Inc. | 2 | $31 |
| USWM, LLC | 2 | $30 |
| Merck | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Sanofi US Services Inc. | 1 | $20 |
| Dermavant Sciences, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$749,129 in reported general payments places this provider in the 95th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 34 | $144,744 |
| TezspireTezepelumab-Ekko | 33 | $136,163 |
| NucalaMepolizumab | 24 | $99,848 |
| XolairOmalizumab | 42 | $93,212 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $91,911 |
| Dupixent PenDupilumab | 21 | $85,831 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $43,496 |
| XhanceFluticasone Propionate | 44 | $32,308 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $29,524 |
| SymbicortBudesonide/Formoterol Fumarate | 90 | $27,152 |
| Spiriva RespimatTiotropium Bromide | 37 | $23,282 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $18,983 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $10,508 |
| DuleraMometasone/Formoterol | 21 | $7,378 |
| Arnuity ElliptaFluticasone Furoate | 28 | $6,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $597,078 | $206,811190 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $804 | $155,281115 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $182 | $91,91113 claims |
| Optinose US, Inc.Xhance | $20,317 | $32,30844 claims |
| MerckDulera | $24 | $7,37821 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $152 | $4,01614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Winston Salem
- Holly McPhersonWinston Salem$179K
- Kent NastasiWinston Salem$31K
- Elizabeth ScannellWinston Salem$12K
- Ingrid HoffmannWinston Salem$9K
- Jason CaldwellWinston Salem$9K
- Craig LaforceRaleigh$7.9M
- Karen DunnRaleigh$3.3M
- Maeve OconnorCharlotte$2.2M
- David CypcarAsheville$1.6M
- Edwin KimChapel Hill$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.